医疗保险共享储蓄计划中的前列腺癌:责任医疗组织是否与前列腺癌男性医疗支出降低相关
该研究利用20%医疗保险样本,比较在责任医疗组织(ACO)与非ACO中治疗的前列腺癌男性的医疗保险支出。共纳入ACO组3297例与非ACO组24,088例局限性前列腺癌男性,采用倾向评分加权回归模型分析。结果显示,ACO状态与支出无显著关联,且治疗类型与支出的交互作用也不显著,按治疗类型分层分析结果一致。
要点
- ACO组3297例与非ACO组24,088例局限性前列腺癌男性,倾向评分加权后比较支出。
- 各治疗方式加权总费用:放疗32,358美元、前列腺切除术27,662美元、期待管理11,134美元。
- 倾向评分加权回归模型中,ACO状态与费用无显著关联,治疗类型与费用的交互作用亦不显著。
核心结论
- 无论治疗类型如何,基于提供者ACO归属的前列腺癌医疗保险支出无显著差异。
研究设计与样本
- 利用20%医疗保险样本,从医疗保险索赔中提取前列腺癌初次诊断后1年的总费用,并通过减去诊断前一年的总费用计算前列腺癌支出。
- 采用倾向评分加权平衡ACO与非ACO组以及不同治疗方式(放疗、前列腺切除术和期待管理)间的基线特征,并使用倾向评分加权回归模型估计平均支出并检验ACO状态与费用的关联。
- 共识别ACO组3297例与非ACO组24,088例局限性前列腺癌男性。
主要发现
- 各治疗方式加权总费用分别为放疗32,358美元、前列腺切除术27,662美元、期待管理11,134美元。
- 在倾向评分加权回归模型中,费用与ACO状态的关联不显著,治疗类型与费用的交互作用也不显著。
- 上述结果在总体分析及按治疗类型分层分析中均一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether Medicare expenditures for men with incident prostate cancer, treated in Accountable Care Organizations (ACOs) differ from those of men treated in non-ACOs. METHODS: Using the 20% Medicare sample, total charges for 1 year following an initial diagnosis of prostate cancer were abstracted from Medicare claims. Prostate cancer expenditures were calculated by subtracting total charges from the year prior to diagnosis. Propensity score weighting was used to balance baseline characteristics of men treated in ACOs and non-ACOs, and between treatment modalities (radiation, prostatectomy, and expectant management). A propensity score weighted regression model was then used to estimate mean expenditures for men with prostate cancer treated in ACOs and non ACOs and to test the association between ACO status and costs. RESULTS: We identified 3297 men treated in ACOs for localized prostate cancer versus 24,088 in the non-ACO cohort. The weighted total charges for each treatment modality were $32,358 (radiation), $27,662 (prostatectomy), and $11,134 (expectant management). In our propensity score weighted regression model, the association between charges and ACO status was not significant, nor was the interaction between treatment type and costs. This was true both overall, and in a stratified analysis by treatment type. CONCLUSIONS: There was no significant difference in Medicare spending on prostate cancer care based on provider ACO affiliation, regardless of treatment type. Although the effects of ACOs on clinical care are complex, this study adds to a growing body of evidence suggesting that ACOs fail to achieve significantly lower charges in certain clinical settings.
引用
- Cole AP, Krasnova A, Ramaswamy A, et al. Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? Prostate Cancer Prostatic Dis. 2019. PMID: 30980025. doi:10.1038/s41391-019-0138-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。